• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 1, 2018

View Archived Issues

Investors pump $100M into Rubius' cell therapy platform

Rubius Therapeutics Inc., a Cambridge, Mass.-based company developing red blood cell-based therapies, has completed an oversubscribed $100 million crossover financing. Read More

Regulatory front

The Saint Regis Mohawk Tribal Council is not waiting for the Patent Trial and Appeal Board (PTAB) to rule on the validity of six Restasis (cyclosporine) patents before appealing the board's decision that tribal sovereign immunity does not apply to inter partes review (IPR) proceedings. Read More

Earnings

Jazz Pharmaceuticals plc, of Dublin, reported total revenue of $436.4 million for the fourth quarter, with full-year 2017 revenue coming in at $1.6 billion. Read More

In the clinic

Acceleron Pharma Inc., of Cambridge, Mass., highlighted the publication of final results from its phase I trial of ACE-083, a locally acting engineered protein therapeutic for the potential treatment of diseases such as facioscapulohumeral dystrophy (FSHD) and Charcot-Marie-Tooth disease. Read More

Appointments and advancements

Fusion Pharmaceuticals Inc., of Hamilton, Ontario, appointed Marc Schwabish senior vice president, business development and U.S. operations. Read More

Other news to note

Beigene Ltd., of Beijing, said Revlimid (lenalidomide) was approved by the CFDA for the treatment of multiple myeloma (MM) in combination with dexamethasone in adult patients with previously untreated MM who are not eligible for transplant. Read More

Financings

Wize Pharma Inc., of Hod Hasharon, Israel, said it received notices from existing stockholders and lenders to exercise investment rights and warrants to purchase an aggregate of about 18.9 million shares of common stock. Read More

Trial recruitment easier in China? Not so fast, according to analysis

HONG KONG – The sheer speed of growth of the biotech and med-tech industries in China has easily outpaced the development of regulation and has led to concerns that too many of the ballooning number of clinical trials in the country fail to meet enrollment targets. Read More

FDA working out kinks to implement security measures for drug supply chain

As the November 2023 deadline for the full implementation of the Drug Supply Chain Security Act (DSCSA) approaches, the FDA continues to meet with stakeholders to work out some of the kinks. Read More

Novo Nordisk Foundation commits $165M to 'Repair' gaps in antibiotic pipeline

LONDON – The Novo Nordisk Foundation is making a move to plug the gap in the antibiotic pipeline, setting up a $165 million venture capital fund to invest in companies involved in discovery and early stage development. Read More

Medimmune spinout secures $250M series A, while Arix seeks $138M

DUBLIN – The steady flow of capital into early stage biopharmaceutical innovation continues unabated, as evidenced by two separate transactions disclosed Wednesday. Astrazeneca plc's Medimmune arm is spinning out a series of pipeline assets into a new venture, Viela Bio Inc., which has secured funding commitments of up to $250 million from a syndicate of investors led by three funds with a strong Chinese orientation. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe